Development of an optimized activatable MMP-14 targeted SPECT imaging probe

Center for Molecular and Functional Imaging, Department of Radiology and Biomedical Imaging, University of California, San Francisco, 185 Berry Street, Suite 350, Box 0946, San Francisco, CA 94107, United States.
Bioorganic & medicinal chemistry (Impact Factor: 2.95). 01/2009; 17(2):653-9. DOI: 10.1016/j.bmc.2008.11.078
Source: PubMed

ABSTRACT Matrix metalloproteinase-14 (MT1-MMP or MMP-14) is a membrane-associated protease implicated in a variety of tissue remodeling processes and a molecular hallmark of select metastatic cancers. The ability to detect MMP-14 in vivo would be useful in studying its role in pathologic processes and may potentially serve as a guide for the development of targeted molecular therapies. Four MMP-14 specific probes containing a positively charged cell penetrating peptide (CPP) d-arginine octamer (r(8)) linked with a MMP-14 peptide substrate and attenuating sequences with glutamate (8e, 4e) or glutamate-glycine (4eg and 4egg) repeating units were modeled using an AMBER force field method. The probe with 4egg attenuating sequence exhibited the highest CPP/attenuator interaction, predicting minimized cellular uptake until cleaved. The in vitro MMP-14-mediated cleavage studies using the human recombinant MMP-14 catalytic domain revealed an enhanced cleavage rate that directly correlated with the linearity of the embedded peptide substrate sequence. Successful cleavage and uptake of a technetium-99m labeled version of the optimal probe was demonstrated in MMP-14 transfected human breast cancer cells. Two-fold reduction of cellular uptake was found in the presence of a broad spectrum MMP inhibitor. The combination of computational chemistry, parallel synthesis and biochemical screening, therefore, shows promise as a set of tools for developing new radiolabeled probes that are sensitive to protease activity.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The noninvasive imaging of matrix metalloproteinases (MMPs) activity in postischemic myocardial tissue holds great promise to predict cardiac function post-myocardial infarction. Consequently, development of MMP specific molecular imaging probes for noninvasive visualization and quantification of MMP activity is of great interest. A novel MMP imaging strategy is based on activatable cell-penetrating peptide probes (ACPP) that are sensitive to the proteolytic activity of MMP-2 and -9. The MMP-mediated activation of these ACPPs drives probe accumulation at the target site. The aim of this study was the development and characterization of radiolabeled MMP-2/9 sensitive ACPPs to assess MMP activity in myocardial remodeling in vivo. Specifically, a short and long-circulating MMP activatable cell-penetrating imaging probe (ACPP and Alb-ACPP, respectively; the latter is an ACPP modified with an albumin binding ligand that prolongs blood clearance) were successfully synthesized and radiolabeled. Subsequently, their biodistributions were determined in vivo in a Swiss mouse model of myocardial infarction. Both peptide probes showed a significantly higher uptake in infarcted myocardium compared to remote myocardium. The biodistribution for dual-isotope radiolabeled probes, which allowed us to discriminate between uncleaved ACPP and activated ACPP, showed increased retention of activated ACPP and activated Alb-ACPP in infarcted myocardium compared to remote myocardium. The enhanced retention correlated to gelatinase levels determined by gelatin zymography, whereas no correlation was found for the negative control: an MMP-2/9 insensitive non-ACPP. In conclusion, radiolabeled MMP sensitive ACPP probes enable to assess MMP activity in the course of remodeling post-myocardial infarction in vivo. Future research should evaluate the feasibility and the predictive value of the ACPP strategy for assessing MMP activity as a main player in postinfarction myocardial remodeling in vivo.
    Molecular Pharmaceutics 03/2014; 11(5). DOI:10.1021/mp400569k · 4.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Photo-dynamic therapy (PDT) is a promising minimally-invasive therapeutic approach to activate oxidative photodamage and subsequent cell death of targeted tumor. The classical non-targeted photosensitizers lack sufficient tumor selectivity and are taken up in the neighboring normal tissues, resulting in undesirable adverse effects. To overcome this obstacle, diverse tumor-targeting approaches 10 have been developed, such as the targeted photodynamic therapy (TPDT). In the present review we have discussed the recently emerged strategies in the designing of targeted photosensitizers for TPDT including target the tumor specific enzyme, photodynamic molecular beacons, the PDT reagents target the acidic microenvironment and target the overexpressed folic acid receptors on the cancer cell surfaces. The approaches used in TPDT, such as passive or active and/or activatable were discussed. The molecular 15 structure assembly and structure function relationship in chemistry as well as biology point of approach were also highlighted
    06/2014; DOI:10.1039/C4TC00659C
  • [Show abstract] [Hide abstract]
    ABSTRACT: Internalization into cancer cells is a significant challenge in the delivery of many anti-cancer therapeutics. Drug carriers can address this challenge by facilitating cellular uptake of cytotoxic cargo in the tumor, while preventing cellular uptake in healthy tissues. Here we describe an extrinsically controlled drug carrier-a nanopeptifier-that amplifies cellular uptake by modulating the activity of cell-penetrating peptides with thermally toggled self-assembly of a genetically encoded polypeptide nanoparticle. When appended with a pro-apoptotic peptide, the nanopeptifier creates a cytotoxic switch, inducing apoptosis only in its self-assembled state. The nanopeptifier provides a new approach to tune the cellular uptake and activity of anti-cancer therapeutics by an extrinsic thermal trigger.
    Nano Letters 03/2014; 14(4). DOI:10.1021/nl5002313 · 12.94 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014